Tìm theo
Pertuzumab
Các tên gọi khác (5 ) :
  • 2C4 Antibody
  • MOAB 2C4
  • Monoclonal Antibody 2C4
  • Omnitarg
  • rhuMAb-2C4
monoclonal antibodies
Thuốc Gốc
Biotech
CAS: 380610-27-5
ATC: L01XC13
PTK: 148 kDa
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Phân tử khối
148 kDa
Cơ Chế Tác Dụng : Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012. Pertuzumab is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, HER3, and HER4) on the surface of cancer cells. The HER signaling pathway plays a role in the formation and growth of numerous cancers, and previous clinical trials of pertuzumab in a single agent setting had suggested clinical activity - including stable disease - in heavily pretreated patients with advanced ovarian and breast cancers.
Dược Động Học :
▧ Absorption :
When an initial dose of 840 mg followed by a maintenance dose of 420 mg every three weeks thereafter is administered, steady-state concentrations were achieved on the first maintenance dose.
▧ Volume of Distribution :
5.12 L
▧ Half Life :
18 days
▧ Clearance :
0.24 L/day
Độc Tính : The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.
Chỉ Định : Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Liều Lượng & Cách Dùng : Solution - Intravenous - 420 mg/14 mL
Dữ Kiện Thương Mại
Nhà Sản Xuất
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB06366
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D05446
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/50242-145-01
Wikipedia
http://en.wikipedia.org/wiki/Pertuzumab
RxList
www.rxlist.com/perjeta-drug.htm
Drugs.com
http://www.drugs.com/perjeta.html
... loading
... loading